Topographic guided laser (TCAT) outcomes using a new vector software program (Phorcides)

Session Details

Session Title: LASIK & PRK I

Session Date/Time: Sunday 15/09/2019 | 16:30-18:00

Paper Time: 17:33

Venue: Free Paper Forum: Podium 3

First Author: : K.Stonecipher USA

Co Author(s): :                                 

Abstract Details

Purpose:

The purpose of this study was to compare standard FDA TCAT outcomes with those of Topographic Manifest Refraction (TMR) and a new vector software program (Phorcides) in a prospective contralateral eye study with one surgeon. Patients were randomly assigned to groups.

Setting:

The setting was one office with one surgery center with one surgeon participating.

Methods:

All patients were treated using the Wavelight Allegretto Excimer Laser EX500 and all patients had femtosecond laser flaps created using the FS200 laser (Alcon, Fort Worth, Tx, USA). There were two arms of the study. The first was a comparison of FDA TCAT treatments versus TMR. The seconds was a comparison of FDA TCAT treatments versus Phorcides. A total of 222 eyes of 111 patients were enrolled in the first arm and a total of 132 eyes of 66 patients were enrolled in the second arm.

Results:

The primary endpoint was postoperative day one uncorrected visual acuity (UCVA) in single eyes and bilaterally. The first study, TCAT versus TMR, 95% versus 88% of patients saw 1.0 (20/20) OU. Single eyes were 55% and 49% saw 1.33 (20/15) respectively. UCVA of 2.0 (20/10) was achieved in 16% OU and 3% with TCAT and 0% with TMR. In the second study, TCAT versus Phorcides, 100% saw 1.0 OU. Single eyes were 60% and 58% saw 1.33 respectively. UCVA of 2.0 was achieved in 33% OU and 3% with Phorcides and 1.5% with TCAT.

Conclusions:

Better than normal vision is our goal in all patients with refractive laser vision correction. This contralateral eye study illustrates those levels being achieved as early as the postoperative day one visit. None of these patients have been enhanced with up to one-year follow-up. The author will discuss current planning software and its utilization in his surgical arena.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company